🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 15/05/2018 | 155,78 | 155,79 | 153,94 | 155,54 | -1,22% | 1,19% | 1.370.000 |
| 14/05/2018 | 156,11 | 158,46 | 155,39 | 157,46 | +0,96% | 1,97% | 1.442.400 |
| 11/05/2018 | 150,75 | 157,53 | 150,62 | 155,97 | +3,28% | 4,58% | 2.242.900 |
| 10/05/2018 | 150,13 | 151,66 | 149,08 | 151,01 | +1,30% | 1,72% | 1.267.600 |
| 09/05/2018 | 148,65 | 150,14 | 146,67 | 149,07 | +0,54% | 2,33% | 1.419.600 |
| 08/05/2018 | 149,45 | 150,00 | 146,95 | 148,27 | -0,82% | 2,04% | 1.147.000 |
| 07/05/2018 | 150,54 | 151,81 | 148,64 | 149,50 | +0,07% | 2,11% | 1.448.800 |
| 04/05/2018 | 148,26 | 152,14 | 147,79 | 149,39 | -0,17% | 2,93% | 2.263.800 |
| 03/05/2018 | 148,32 | 150,30 | 145,78 | 149,64 | +0,11% | 3,05% | 1.518.900 |
| 02/05/2018 | 151,32 | 153,16 | 148,96 | 149,47 | -1,97% | 2,78% | 2.565.200 |
| 01/05/2018 | 153,14 | 154,70 | 150,40 | 152,48 | -0,44% | 2,81% | 1.648.600 |
| 30/04/2018 | 157,16 | 157,79 | 153,15 | 153,16 | -1,85% | 2,95% | 1.717.300 |
| 27/04/2018 | 157,50 | 159,05 | 153,33 | 156,05 | -1,74% | 3,63% | 1.866.400 |
| 26/04/2018 | 156,60 | 160,85 | 155,83 | 158,81 | +2,36% | 3,21% | 1.991.100 |
| 25/04/2018 | 155,49 | 157,42 | 154,13 | 155,15 | -0,33% | 2,12% | 1.313.100 |
| 24/04/2018 | 160,27 | 160,50 | 154,69 | 155,67 | -1,90% | 3,63% | 1.504.900 |
| 23/04/2018 | 158,71 | 160,13 | 157,74 | 158,69 | +0,34% | 1,51% | 1.154.600 |
| 20/04/2018 | 159,61 | 160,78 | 157,09 | 158,15 | -0,88% | 2,31% | 1.534.700 |
| 19/04/2018 | 162,33 | 162,82 | 159,04 | 159,55 | -2,33% | 2,33% | 1.235.600 |
| 18/04/2018 | 165,00 | 166,12 | 162,66 | 163,36 | -0,99% | 2,10% | 1.122.100 |
| 17/04/2018 | 160,54 | 165,60 | 159,45 | 164,99 | +3,96% | 3,83% | 2.399.400 |
| 16/04/2018 | 163,01 | 163,71 | 158,07 | 158,70 | -1,67% | 3,46% | 1.482.900 |
| 13/04/2018 | 163,08 | 163,08 | 160,41 | 161,39 | -0,36% | 1,64% | 1.486.100 |
| 12/04/2018 | 159,54 | 163,45 | 159,54 | 161,98 | +1,94% | 2,45% | 1.079.900 |
| 11/04/2018 | 159,52 | 162,94 | 158,10 | 158,89 | -1,41% | 3,03% | 1.527.000 |
| 10/04/2018 | 159,04 | 161,72 | 157,77 | 161,17 | +2,81% | 2,48% | 1.264.200 |
| 09/04/2018 | 156,26 | 160,39 | 155,67 | 156,76 | +1,63% | 3,02% | 1.235.400 |
| 06/04/2018 | 155,74 | 157,59 | 152,60 | 154,25 | -2,16% | 3,20% | 1.446.300 |
| 05/04/2018 | 162,82 | 163,49 | 157,12 | 157,66 | -2,75% | 3,91% | 1.352.800 |
| 04/04/2018 | 156,37 | 162,45 | 154,60 | 162,12 | +2,37% | 5,02% | 1.832.000 |